Rational combination with an immunotherapy backbone in genitourinary cancers
Journal
Urological Science
Journal Volume
31
Journal Issue
1
Pages
4-7
Date Issued
2020
Author(s)
Abstract
Immunotherapy, especially immune checkpoint blockade treatment, has changed the landscape of anticancer therapy. In genitourinary (GU) cancer, the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) blockade alone has resulted in improved outcomes compared with conventional therapies, such as chemotherapy and targeted therapy in advanced urothelial carcinoma and renal cell carcinoma (RCC), respectively. To improve the efficacy of the PD-1/PD-L1 blockade, a combination of this blockade with other therapeutic modalities has been explored in the earnest. In a recent study, ipilimumab, an anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, combined with nivolumab, an anti-PD-1 monoclonal antibody as the first-line therapy, has demonstrated superior efficacy to sunitinib in advanced RCC patients with International Metastatic RCC Database Consortium intermediate and poor risk. This mini-review article focuses on the rational combination with the PD-1/PD-L1 blockade in GU cancers. ? 2020 Iranian Journal of Nursing and Midwifery Research - Published by Wolters Kluwer -Medknow.
SDGs
Other Subjects
ipilimumab; nivolumab; sunitinib; cancer combination chemotherapy; cancer immunotherapy; drug efficacy; human; priority journal; renal cell carcinoma; Review; transitional cell carcinoma; urogenital tract cancer
Publisher
Wolters Kluwer Medknow Publications
Type
review